Regencell Bioscience Holdings Ltd

NASDAQ RGC

Data sourced from iex and EODHD
Download Data

Regencell Bioscience Holdings Ltd Free Cash Flow for the year ending June 30, 2023: USD -4.99 M

Regencell Bioscience Holdings Ltd Free Cash Flow is USD -4.99 M for the year ending June 30, 2023, a 17.49% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.
  • Regencell Bioscience Holdings Ltd Free Cash Flow for the year ending June 30, 2022 was USD -6.05 M, a -688.20% change year over year.
  • Regencell Bioscience Holdings Ltd Free Cash Flow for the year ending June 30, 2021 was USD -767.31 K, a 9.13% change year over year.
  • Regencell Bioscience Holdings Ltd Free Cash Flow for the year ending June 30, 2020 was USD -844.41 K, a -115.97% change year over year.
  • Regencell Bioscience Holdings Ltd Free Cash Flow for the year ending June 30, 2019 was USD -390.99 K, a -100.25% change year over year.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email